^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mirzotamab clezutoclax (ABBV-155)

    i
    Associations
    News

    Trials

    Company:
    AbbVie
    Drug class:
    Bcl-xL inhibitor, B7-H3-targeted antibody-drug conjugate
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors (NCT03595059)
    Phase 1
    AbbVie
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    07/13/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    EGFR • HER-2 • BRAF • ALK • ROS1
    |
    PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)